[1] Sung H, Ferlay J, Siegel RL, et al.Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 2021, 71(3):209-249.
[2] Garrido A, Djouder N. Cirrhosis: A Questioned Risk Factor for Hepatocellular Carcinoma. Trends Cancer, 2021, 7 (1): 29-36.
[3] Cabibbo G, Petta S, Barbara M, et al; Italian Liver Cancer (ITA.LI.CA) group. Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. J Hepatol, 2017, 67 (1):65-71.
[4] Iavarone M, Cabibbo G, Piscaglia F, et al; SOFIA (SOraFenib Italian Assessment) study group. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology, 2011, 54 (6):2055-2063.
[5] Iavarone M, Cabibbo G, Biolato M, et al. Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib. Hepatology, 2015, 62(3):784-791.
[6] Reig M, Cabibbo G. Antiviral therapy in the palliative setting of HCC (BCLC-B and -C). J Hepatol, 2021, 74 (5):1225-1233.
[7] Peng Y, Wei Q, He Y, et al. ALBI versus child-pugh in predicting outcome of patients with HCC: A systematic review. Expert Rev Gastroenterol Hepatol, 2020, 14(5):383-400.
[8] 中华医学会肝病学分会.肝硬化诊治指南. 临床肝胆病杂志, 2019, 35(11): 2408-2425.
[9] Kok B, Abraldes JG. Child-Pugh Classification: Time to Abandon? Semin Liver Dis, 2019, 39(1):96-103.
[10] Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol, 2015, 33(6):550-558.
[11] Demirtas CO, D'Alessio A, Rimassa L, et al. ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma. JHEP Rep, 2021, 3(5):100347.
[12] Bannaga A, Arasaradnam RP. Neutrophil to lymphocyte ratio and albumin bilirubin grade in hepatocellular carcinoma: A systematic review. World J Gastroenterol, 2020, 26(33):5022-5049.
[13] Tian BW, Yan LJ, Ding ZN, Liu H, et al. Evaluating liver function and the impact of immune checkpoint inhibitors in the prognosis of hepatocellular carcinoma patients: A systemic review and meta-analysis. Int Immunopharmacol, 2023.
[14] Ruf A, Dirchwolf M, Freeman RB. From Child-Pugh to MELD score and beyond: Taking a walk down memory lane. Ann Hepatol, 2022, 27(1):100535.
[15] Common Terminology Criteria for Adverse Events (CTCAE) Version 5. November 27. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute.
[16] El Hajra I, Sanduzzi-Zamparelli M, Sapena V, et al. Outcome of patients with hepatocellular carcinoma and liver dysfunction under immunotherapy: a Systematic review and meta-analysis. Hepatology, 2023, 77 (4):1139-1149
[17] Kudo M, Matilla A, Santoro A, et al. CheckMate 040 cohort 5: a phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. J Hepatol, 2021, 75 (3):600-609.
[18] Concato J, Corrigan-Curay J. Real-World Evidence-Where Are We Now? N Engl J Med, 2022, 386(18):1680-1682. |
